We are proud to partner with Oncopeptides to expand access to Pepaxti® across Central and Eastern Europe.
A targeted therapy for patients with multiple myeloma who have run out of options, fully approved and finally within reach for patients across our region.
Multiple myeloma does not stop at borders. But access to innovative treatments often does.
In CEE, the gap between regulatory approval and actual patient access can be years. Different reimbursement systems, different market dynamics, different regulatory timelines in every single country. That gap costs lives.
This is exactly why Salus Group exists. For decades we have been bridging that gap, market by market, therapy by therapy. Not because it is easy, but because making health accessible is the only way we know how to do this work.
